A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS)

Trial Profile

A Phase I, sequential group, randomized, double-blind, placebo-controlled study to assess the tolerability and safety of escalating doses of oral laquinimod administered daily in subjects with relapsing remitting multiple sclerosis (RRMS)

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2014

At a glance

  • Drugs Laquinimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Biomarker
  • Sponsors Teva Pharmaceutical Industries
  • Most Recent Events

    • 03 May 2014 Pharmacokinetic results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 29 Apr 2014 Results presented at the 66th Annual Meeting of the American Academy of Neurology.
    • 29 Apr 2014 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top